Intellect Neurosciences, Inc. Obtains OX1 Phase 1b Draft Report Showing the Company's Lead Alzheimer's Candidate Was Safe and Well-Tolerated at All Dose Levels Tested
27 oct. 2010 06h30 HE
|
Intellect Neurosciences, Inc.
NEW YORK, Oct. 27, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
Intellect Neurosciences Issues Letter to Shareholders
13 oct. 2010 10h24 HE
|
Intellect Neurosciences, Inc.
NEW YORK, Oct. 13, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences, Inc. Obtains New Patent for Alzheimer Monoclonal Antibodies From the United States Patent and Trademark Office; Milestone Supports Company's Mission to Develop Innovative Disease Modifying Treatments for Alzheimer's Disease
05 oct. 2010 08h00 HE
|
Intellect Neurosciences, Inc.
NEW YORK, Oct. 5, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses...
Intellect Neurosciences CEO to Deliver Key Note Speech on the Development of Novel Alzheimer's Therapeutics at Medical Conference in Ireland
20 sept. 2010 08h48 HE
|
Intellect Neurosciences, Inc.
NEW YORK, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with both internal preclinical and clinical-stage pipelines, as well as multiple...
Intellect Neurosciences Launches New Website
14 sept. 2010 08h00 HE
|
Intellect Neurosciences, Inc.
NEW YORK, Sept. 14, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents...
Intellect Neurosciences Issues Letter to Shareholders
08 sept. 2010 08h30 HE
|
Intellect Neurosciences, Inc.
NEW YORK, Sept. 8, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Former Head of Discovery Translational Medicine at Wyeth Research and Pfizer Joins Intellect Neurosciences, Inc. as Key Consultant
07 sept. 2010 08h00 HE
|
Intellect Neurosciences, Inc.
NEW YORK, Sept. 7, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
Intellect Neurosciences to Participate in Rodman & Renshaw 2010 Annual Global Investment Conference in New York on September 14, 2010
01 sept. 2010 09h10 HE
|
Intellect Neurosciences, Inc.
NEW YORK, Sept. 1, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
Intellect Neurosciences, Inc. CEO Comments on Recent Events in the Development of Novel Alzheimer's Therapies
19 août 2010 15h13 HE
|
Intellect Neurosciences, Inc.
NEW YORK, Aug. 19, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
Intellect Neurosciences, Inc. Locks Database for OX1 Phase 1b Clinical Trial
18 août 2010 08h08 HE
|
Intellect Neurosciences, Inc.
NEW YORK, Aug. 18, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...